Cellectricon September newsletter

Can’t see this email properly?

View Online
Intro image

Join us for the IASP World Congress on Pain!


Welcome to our September Newsletter where we have a special focus on the ongoing IASP World Congress of Pain which is being held in Boston, MA.


This conference poses a great opportunity for sharing the latest developments in the field of pain research. At the meeting, our CSO Paul Karila will together with esteemed collaborators present two posters describing our work on providing the scientific community with the most predictive chronic pain in vitro models possible. 

In other news, we are pleased to welcome Dr. Annika Malmberg to our advisory board. Annika is an experienced neurobiologist and pharmacology expert with a strong pharma background and will support our business development team.

Please do not hesitate to stop by the posters or reach out to arrange a meeting while in Boston!



Image Annika Malmberg

Dr. Annika Malmberg joins Cellectricon's Strategic Advisory Board


With more than 20 years experience from working with drug discovery and development at both biotechs and pharmaceutical companies, Dr. Malmberg will play an important role in supporting Cellectricon’s commercial strategy development.


Learn More


Poster presentations at IASP WCP:


Examination of the Role of Nav1.7 and Nav1.8 in the Generation of Action Potentials both In Vivo and In Vitro


In collobration with the Department of Neuroscience, Genentech


Poster number: PTH114
Presentation time: Thursday, September 13, 9:30 – 10:30 AM


Poster info


Disease Relevance In Vitro? Comparison of Excitability in DRG Neurons from Neuropathic and Inflammatory Disease Models


In collaboration with the Department of Physiology and Pharmacology, Karolinska Institutet

Poster number: PTH241
Presentation time: Thursday, September 13, 3:15 – 4:15 PM


Poster info

Cellectricon Discovery Services

Functional and morphological screening in neurons


At Cellectricon we have a particular focus on diseases where neuronal excitability and synaptic function matters, such as chronic pain, epilepsy, Alzheimer’s disease and schizophrenia. With our discovery platform, we can create model systems for registering changes in neural activity, both at the cellular and network level.

The heart of our discovery platform is our proprietary Cellaxess® Elektra technology, a revolutionary automated platform for functional screening in living neurons. The system combines localized electric field manipulation with high speed fluorescence imaging to monitor parameters such as neuronal excitability, synaptic efficacy and synaptic plasticity in primary and stem cell-derived neurons. Cellaxess® Elektra is the only system enabling high quality phenotypic assays for compound characterization and target validation in a high-throughput format for these parameters


Learn more


Upcoming events:





4th Annual Neuroscience R&D Technologies conference


Munich, Germany

Don't miss the presentation by Dr. Paul Karila titled:
"Novel approaches and concepts for development of functional in vitro assays targeting neurodegenerative disease discovery"



Cellectricon AB, Flöjelbergsgatan 8C, SE-431 37 Mölndal, Sweden, Org. No: 556602-0896
Phone: +46 (0)31 760 35 00    E-mail: info@cellectricon.com
This email has been sent to [email address suppressed] as a subscriber to Cellectricon AB.
If you no longer wish to receive these emails, please unsubscribe .